Please login to the form below
tenofovir
This page shows the latest tenofovir news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations
Gilead Sciences (Gilead) has announced that the European Commission (EC) has authorised a new low-dose tablet dosage form of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and an extension of its indication
Latest news
-
Gilead’s Vemlidy gets FDA approval for paediatric patients with chronic hepatitis B infection
Gilead Sciences (Gilead) supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25mg tablets to treat chronic hepatitis B virus (HBV) infection in paediatric patients 12 years and older with compensated
-
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
The studies demonstrated that cabotegravir long-acting for PrEP was superior to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), with clinical trial participants experiencing a 69% lower rate of HIV
-
Gilead’s latest Biktarvy data offers hope to HIV patients
which highlighted Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) as a generally well-tolerated and efficacious regimen, regardless of prior treatment and comorbidity status in people
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Without the Veklury bump, total product sales decreased by 3% to $5.4bn for the third quarter, primarily due to the loss of exclusivity of HIV combination therapies Truvada (emtricitabine/tenofovir ... The drop was also partially offset by a 20% increase
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
However, total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020, due to the loss of exclusivity of its HIV drugs Truvada, tenofovir disoproxil fumarate and
More from news
Approximately 9 fully matching, plus 103 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
-
Pharma deals during July 2012
Merck has licensed CMX 157 an oral nucleoside reverse transcriptase inhibitor for treatment of HIV that is 200-fold more potent in vitro than tenofovir (Gilead's product with sales of
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
10. Tenofovir – a nucleotide reverse transcriptase inhibitor (NtRTI). 11. Acts as a nucleotide analogue that competitively inhibits reverse transcriptase, the enzyme required for replication of the viral genome.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- The state of pharma customer experience
- GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
